Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Cook

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
The Journal of Pharmacology and Experimental Therapeutics|March 23, 1999
Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosisJ J Cook, S J Gardell, M A Holahan, et al.
Journal of Medicinal Chemistry|July 8, 1999
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregationM S Egbertson, J J Cook, B Bednar, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorptionR C Isaacs, K J Cutrona, C L Newton, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1996
Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217J J Cook, M A Holahan, E A Lyle, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitorP E Sanderson, K J Cutrona, B D Dorsey, et al.
Journal of Medicinal Chemistry|June 6, 1997
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonistsB C Askew, R A Bednar, B Bednar, et al.
Journal of Medicinal Chemistry|February 17, 1998
Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid supportS F Brady, K J Stauffer, W C Lumma, et al.
Journal of Medicinal Chemistry|August 14, 1998
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 positionT J Tucker, S F Brady, W C Lumma, et al.
Journal of Medicinal Chemistry|November 7, 1998
Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templatesP E Sanderson, T A Lyle, K J Cutrona, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
The Journal of Pharmacology and Experimental Therapeutics|March 23, 1999
Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosisJ J Cook, S J Gardell, M A Holahan, et al.
Journal of Medicinal Chemistry|July 8, 1999
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregationM S Egbertson, J J Cook, B Bednar, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorptionR C Isaacs, K J Cutrona, C L Newton, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1996
Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217J J Cook, M A Holahan, E A Lyle, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitorP E Sanderson, K J Cutrona, B D Dorsey, et al.
Journal of Medicinal Chemistry|June 6, 1997
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonistsB C Askew, R A Bednar, B Bednar, et al.
Journal of Medicinal Chemistry|February 17, 1998
Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid supportS F Brady, K J Stauffer, W C Lumma, et al.
Journal of Medicinal Chemistry|August 14, 1998
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 positionT J Tucker, S F Brady, W C Lumma, et al.
Journal of Medicinal Chemistry|November 7, 1998
Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templatesP E Sanderson, T A Lyle, K J Cutrona, et al.
Pageof 5